These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 9476147)
1. Clinical relevance of P-glycoprotein with respect to the application of resistance modifiers. Scheulen ME Int J Clin Pharmacol Ther; 1998 Jan; 36(1):41-5. PubMed ID: 9476147 [No Abstract] [Full Text] [Related]
2. [Overcoming the multiple drug resistance of tumors]. Donenko FV; Sitdikova SM; Moroz LV Vopr Onkol; 1991; 37(11-12):1034-41. PubMed ID: 1688278 [No Abstract] [Full Text] [Related]
3. Drug resistance in hematologic malignancies. Dalton W Clin Adv Hematol Oncol; 2005 Apr; 3(4):267-8. PubMed ID: 16166998 [No Abstract] [Full Text] [Related]
4. [Calcium antagonist as biological modulator in cancer chemotherapy]. Tsuruo T Nihon Rinsho; 1989 Aug; 47(8):1851-6. PubMed ID: 2573744 [No Abstract] [Full Text] [Related]
5. [The molecular mechanisms of the multiple drug resistance of tumors]. Leont'eva OV Antibiot Khimioter; 1995 May; 40(5):48-60. PubMed ID: 8534182 [No Abstract] [Full Text] [Related]
6. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Fox E; Bates SE Expert Rev Anticancer Ther; 2007 Apr; 7(4):447-59. PubMed ID: 17428165 [TBL] [Abstract][Full Text] [Related]
7. [Oncobiogram and its significance in the choice and efficacy of cytostatic therapy]. Savran VR Vopr Onkol; 1983; 29(3):106-13. PubMed ID: 6340347 [No Abstract] [Full Text] [Related]
8. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Kaye SB Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854 [TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance reversal agents. Robert J; Jarry C J Med Chem; 2003 Nov; 46(23):4805-17. PubMed ID: 14584929 [No Abstract] [Full Text] [Related]
10. [Update on mechanisms of drug resistance]. Chauffert B; Correia M; Sergent C Bull Cancer; 1999 Jan; 86(1):97-103. PubMed ID: 10029712 [No Abstract] [Full Text] [Related]
11. Modeling therapy resistance in genetically engineered mouse cancer models. Rottenberg S; Jonkers J Drug Resist Updat; 2008; 11(1-2):51-60. PubMed ID: 18165147 [TBL] [Abstract][Full Text] [Related]
12. Introduction: chemotherapies in the treatment of breast cancer. Fojo AT Semin Oncol; 2005 Dec; 32(6 Suppl 7):S1-2. PubMed ID: 16360715 [No Abstract] [Full Text] [Related]
15. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831 [TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanisms of the occurrence of tumor drug resistance and ways to overcome it]. Belousova AK Vopr Onkol; 1978; 24(5):92-104. PubMed ID: 351956 [No Abstract] [Full Text] [Related]
17. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112 [TBL] [Abstract][Full Text] [Related]
18. Conditions of drug delivery within solid tumors, and noninvasive methods for studies in humans. Port RE Int J Clin Pharmacol Ther; 1997 Feb; 35(2):78-9. PubMed ID: 9147714 [No Abstract] [Full Text] [Related]
19. [Segidrin: a new-type antineoplastic agent]. Filov VA Vopr Onkol; 1994; 40(1-3):3-14. PubMed ID: 7701790 [No Abstract] [Full Text] [Related]